VJHemOnc openbaar
[search 0]
Meer

Download the App!

show episodes
 
The Video Journal of Hematological Oncology (VJHemOnc) podcast covers the latest hematological oncology and hematology news from international experts – from leukemias, lymphomas, MDS and MPNs, to sickle cell, aplastic anemia and rare diseases. Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinion. If you enjoy the podcast, please leave us a rating and r ...
 
Loading …
show series
 
Over the last two decades the outcomes of patients with amyloidosis have substantially improved with timely diagnosis, the use of chemotherapeutic agents and improved patient selection for autologous stem cell transplantation (ASCT); however, for patients who are diagnosed at later stages or who are ineligible for ASCT the prognosis is poorer. Rece…
 
Currently, five chimeric antigen receptor T-cell (CAR-T) therapies are approved for the treatment of hematological malignancies including acute lymphoblastic leukemia, B-cell lymphoma, non-Hodgkin lymphoma and multiple myeloma. Despite reporting high response rates, the use of CAR-T therapy is associated with a number of practical challenges, inclu…
 
The treatment of chronic myeloid leukemia (CML) has substantially evolved since the FDA approval of the tyrosine kinase inhibitor imatinib in 2001 - the first targeted therapy for CML. Since then, several second- and third- generation TKIs have emerged in the field, as well as other novel therapies. Despite this, around 20-30% of patients with CML …
 
Continuous therapy has been a key aspect of the standard of care approaches for the treatment of multiple myeloma for many years, prolonging disease control and improving progression-free survival in comparison to fixed-duration approaches; however, it is now being discussed whether treatment-free interval strategies could be incorporated into the …
 
The management of chronic lymphocytic leukemia (CLL) has evolved drastically over the last few years, with the introduction of novel therapies and the identification of new genetic markers. The current most effective therapies for CLL include venetoclax, obinutuzumab and BTK inhibitors, whilst ongoing clinical trials are investigating the use of BT…
 
Measurable residual disease (MRD) is emerging as an important prognostic marker in the management of multiple myeloma. Promising clinical evidence from trials, such as the MYELOMA XI trial, has linked MRD-negativity to improved outcomes in myeloma. Whilst research into MRD as a prognostic marker continues, MRD is further being explored as a tool to…
 
Autologous stem cell transplantation (ASCT) has been the standard of care patients with multiple myeloma for the past three decades; however, high-risk patients still have poor outcomes. Many bispecific antibody therapies are currently under investigation for the treatment of myeloma, such as blinatumomab, teclistamab, talquetamab and cevostamab, a…
 
Antibody therapies are rapidly transforming the treatment landscape of non-Hodgkin lymphoma (NHL). Since the development of rituximab as an anti-CD20 antibody, there has been an intense research interest in antibody-based therapeutic approaches. The use of antibody-drug conjugates, monoclonal antibodies, and bispecific antibodies are increasingly b…
 
A significant number of patients with acute myeloid leukemia (AML) are unable to withstand intensive chemotherapy regimens due to older age and the presence of comorbidities, creating an unmet medical need. Recent advances in the understanding of the genomics underlying AML have led to the development of therapies targeting FLT3, IDH1/2 and BCL-2. …
 
Janus kinase (JAK) inhibitors are becoming an increasingly prominent class of drug in the treatment of myeloproliferative neoplasms (MPNs), in particular for the management of myelofibrosis symptoms. With the FDA approval of ruxolitinib in 2011 followed by the approval of fedratinib in 2019, JAK inhibitors are already established in the myelofibros…
 
Great progress has been made in the treatment of acute lymphocytic leukemia (ALL), primarily owing to the development of targeted therapies such as monoclonal antibodies and tyrosine kinase inhibitors. The use of targeted therapies has significantly improved survival outcomes for patients with ALL and has become a mainstay of frontline treatment. S…
 
Many clinical trials are currently investigating the potential benefits of interferons in the treatment of myeloproliferative neoplasms (MPNs), in particular for polycythemia vera, essential thrombocythemia and myelofibrosis. Interferon-alfa was originally explored for MPN treatment many years ago, however it’s frequent dosing and toxicity profile …
 
Real-world data gained through scientific studies is essential in the advancement of treatments for all hematologic malignancies. Historically, pharmaceutical companies have been restricted to randomized clinical trials as their only form of testing a treatment. However, due to technological advancement, there are now ways in which data from real-w…
 
Over the past two decades the treatment landscape for non-Hodgkin lymphoma (NHL) has rapidly evolved, with the development of Bruton’s tyrosine kinase (BTK) inhibitors making a particularly significant impact and opening the door to the possibility of chemotherapy-free regimens. In 2013, ibrutinib became the first BTK inhibitor to receive FDA appro…
 
Research into the treatment of non-Hodgkin lymphoma (NHL) has made great progress within the last decade, with clinical trials such as the TRANSCEND-OUTREACH-007 and ZUMA-12 studies successfully advancing into later phases. Although there are currently various approaches to NHL treatment, primarily employing chemotherapy, steroid medication and all…
 
Immunotherapies are showing increasingly promising results for the treatment of patients with non-Hodgkin lymphoma (NHL) and, in particular, bispecific antibodies have demonstrated promising clinical results in heavily pre-treated patients. Several bispecific antibodies have entered the early stages of clinical trials since the approval of the CD19…
 
At present, four types of chimeric antigen receptor T-cell (CAR-T) therapy are FDA approved for specific types of lymphoma: for relapsed or refractory (R/R) mantle cell lymphoma, brexucabtagene autoleucel, for R/R follicular lymphoma, axicabtagene ciloleucel, and for some aggressive forms of non-Hodgkin lymphoma, axicabtagene ciloleucel, tisagenlec…
 
Although classical Hodgkin lymphoma has a high cure and overall survival rate, the treatment of relapsed/refractory disease, treatment-related adverse events, quality of life and poor outcomes in older patients present ongoing unmet needs. Much research is currently focused on risk stratification, such as with positive emission tomography (PET) sca…
 
Hematopoietic stem cell transplantation (HSCT) is used as a treatment option for a wide variety of hematological disorders. Graft-versus-host disease (GvHD) is a systemic disorder that arises when the graft’s immune cells recognize the host as foreign and attack the recipient’s body cells. Its occurrence poses a major medical complication that limi…
 
The treatment of multiple myeloma is a rapidly evolving field with advances in the understanding of myeloma disease biology contributing to the development of novel targeted therapies. Recently, there has been a rapid increase in the number of chimeric antigen receptor (CAR) T-cell therapies being trialed for patients with multiple myeloma, and in …
 
In this roundtable discussion, chaired by Gilles Salles, MD, PhD, Memorial Sloan Kettering, New York, NY; Nirav N. Shah, MD, Medical College of Wisconsin, Brookfield, WI; Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria; Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MI, review the most exciting updates in lymphoma from the 2021 Eu…
 
In this roundtable discussion, chaired by Paolo Ghia, MD, PhD, Università Vita-Salute San Raffaele, Milan, Italy; Susan O’Brien, MD, University of California Irvine, Irvine, CA; Lydia Scarfò, MD, Università Vita-Salute San Raffaele, Milano, Italy and Othman Al-Sawaf, MD, University Hospital of Cologne, Cologne, Germany, review the most exciting upd…
 
Myelodysplastic syndromes (MDS) are a group of myeloid clonal disorders caused by a defect in bone marrow, which hinders their ability to produce healthy and normal functioning red blood cells (RBCs). The heterogeneous nature of MDS means therapeutic approaches need to be specifically tailored to each subtype. Current treatment options for MDS incl…
 
Recent progress in the field of immunotherapy presents an exciting alternative to standard chemotherapy treatments for patients with non-Hodgkin lymphoma. However, at present, durable responses are only achieved in a minority of patients. Accumulating evidence suggests that the microenvironment plays a critical role in the regulation of immunothera…
 
The introduction of many novel drug classes and therapies has resulted in significant improvements in overall survival outcomes for patients with multiple myeloma over the past decade. Despite this, many patients become relapsed or refractory to currently available therapies and as such, novel agents and combination regimens remain key to improving…
 
The breakthrough discovery of upregulation of the JAK-STAT signaling pathway as the driving force behind myeloproliferative neoplasms (MPNs) has led to a broadened range of treatment options across the spectrum of MPNs. Myelofibrosis is one of the most common types of MPN and many clinical trials are exploring novel drugs and combinations for its t…
 
Over the past decade there has been a vast increase in the number of clinical trials taking place in the field of myeloproliferative neoplasms (MPNs), with many trials investigating the potential benefits of novel JAK inhibitors both as monotherapy and in combination with other drugs, such as Bcl-2, Bcl-xL or BET inhibitors. More recently, next-gen…
 
Treatment options for patients with myelodysplastic syndromes (MDS) remain limited, with the rapid advances seen in other hematological malignancies not replicated in this space. Aside from hematopoietic stem cell transplantation, current approaches are non-curative, instead aiming to delay disease progression and manage cytopenias. The development…
 
Over the last years, the chronic lymphocytic leukemia (CLL) field has seen significant growth in new drugs and new treatment combinations. One emergent strategy is fixed-duration therapy, which combines two or more agents for a set timeframe. Fixed-duration therapy is an appealing option for different reasons, including shorter treatment times and …
 
Acute myeloid leukemia (AML) is a clonal hematologic malignancy defined by genetic heterogeneity due to recurrent gene mutations. Precision medicine has gained importance in the treatment of AML, with important developments in gene mutation-targeted therapeutic agents transforming the treatment landscape. The role of measurable residual disease (MR…
 
The treatment and management of multiple myeloma has evolved drastically over the last ten years with the introduction of many novel drug classes and therapies, resulting in notable improvements in overall survival. However, many patients remain relapsed or refractory and thus clinical trials of novel agents and combinations are key to improving th…
 
There are several forms of acute lymphoblastic leukemia (ALL), with B-cell ALL being the most common (~75% of cases). A range of treatments are available for ALL, including chemotherapy, radiation therapy, and stem cell transplantation. Chimeric antigen receptor T-cell (CAR-T) therapy is a novel cellular therapy that has demonstrated potential for …
 
During the COVID-19 pandemic, myeloma support and advocacy groups were forced to adapt to a new way of working in order to continue helping patients with myeloma and improving their quality of life. The COVID-19 pandemic has changed the way that patients with myeloma interact with their doctors, with phone and video appointments filling in for face…
 
Over the past ten years, the approval of several new and effective therapies for multiple myeloma has significantly improved overall survival outcomes. The introduction of novel therapies has led to high levels of complete response, and many novel techniques are now being explored for the assessment of the depth of response, one of the most effecti…
 
Chronic lymphocytic leukemia (CLL) is slow to develop and can be hard to treat as patients relapse or become refractory to currently available therapies. Chimeric antigen receptor T-cell (CAR-T) therapy is a novel type of treatment which is currently being explored for several forms of hematological cancer, with FDA approvals of CAR-T therapies for…
 
Age is an important prognostic factor in multiple myeloma, with patients aged over 75 years showing inferior outcomes when compared to younger patients. Several factors play into the poor survival observed, including a higher incidence of severe disease, and high rates of comorbid conditions and functional impairment. However, the elderly populatio…
 
Advances in both the treatment landscape and the pathology of the disease have improved the outcome of children and adults with acute lymphoblastic leukemia (ALL). However, many challenges still remain, including the treatment of older patients with ALL, diagnosis of Philadelphia chromosome-like (Ph-like) ALL, a newly identified aggressive subtype,…
 
Myelodysplastic syndromes (MDS) are a heterogenous group of myeloid disorders characterized by the accumulation of dysplastic cells within the bone marrow, resulting in ineffective hematopoiesis and cytopenia. Around 30% of patients with MDS will progress to acute myeloid leukemia (AML). Hematopoietic stem cell transplantation (HSCT) currently repr…
 
Acute myeloid leukemia (AML) is the most common type of leukemia in adults and is highly heterogenous. AML is typically treated with chemotherapy and allogeneic stem cell transplantation, however not all patients are eligible or able to tolerate these regimens, and many patients will experience relapse. Chimeric antigen receptor T-cell (CAR-T) ther…
 
Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid disorders characterized by the accumulation of dysplastic cells within the bone marrow, resulting in ineffective hematopoiesis and cytopenia. Patients typically have a median survival of 0.8 to 8.8 years. Around 30% of patients with MDS will progress to acute myeloid leukemia (AML…
 
The management of post-transplantation relapse and immune attack is an ongoing battle in patients undergoing bone marrow transplants. The efficacy and safety of therapy options for graft-versus-host disease is part of a larger conversation aimed at improving the outcomes of patients after transplantation. Ongoing research has seen interesting direc…
 
The treatment of aggressive lymphomas such as diffuse large B-cell has seen dramatic changes, and with the advent of bispecific monoclonal antibodies, there is hope for a wider demographic of patients. Due to the COVID-19 pandemic, the 62nd American Society of Hematology (ASH) 2020 Annual Meeting and Exposition (ASH 2020) was held virtually – and i…
 
The International Symposium on Hodgkin Lymphoma (ISHL) 2021 Hodgkin Lymphoma (HL) update gathered an international panel to discuss the most recent developments in HL, and provided a comprehensive update on current and emerging concepts. In this podcast, we spoke to Sven Borchmann, MD, of the University Hospital Cologne, Cologne, Germany, Paul Jan …
 
The development of immunomodulatory agents and proteasome inhibitors alongside stem cell transplantation and chemotherapy has significantly improved the treatment options for patients with myeloma. Recently, B-cell maturation antigen (BCMA) has emerged as a promising target for myeloma treatment due to its selective expression in malignant plasma c…
 
The European Group for Blood and Marrow Transplantation (EBMT) Trainee Committee was established in 2021 to address the needs of trainees in the field of bone marrow transplant and cellular therapy and provide advice and support for trainees. The group, composed of trainees, young investigators, and students, wants to encourage trainees to establis…
 
The most common form of amyloidosis, light-chain (AL) amyloidosis, results from abnormalities in plasma cells causing them to produce abnormal amyloid fibrils made up of immunoglobulin light chains. These insoluble fibrils deposit extracellularly and accumulate within organs such as the heart, kidneys, liver, spleen, nervous system, and digestive t…
 
The 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) was held virtually this year and showcased the latest advances in the field of transplantation and cellular therapies. VJHemOnc is joined by Christian Chabannon, MD, PhD, Institut Paoli Calmettes, Marseille, France, who chaired an insightful discussion on the …
 
Acute myeloid leukemia (AML) is the most common type of adult leukemia, with over 19,500 new cases estimated to be diagnosed per year in the US alone. According to the NIH, 27.4% of people diagnosed with AML will survive for five years or more. AML is typically treated with a combination of cytarabine and anthracycline-based chemotherapy regimens, …
 
Chronic lymphocytic leukemia (CLL), also known as B-cell CLL (B-CLL) is the most common leukemia in Europe and North America. CLL progresses slowly and is generally incurable, with the majority of patients showing relapse and having short remissions. Over the past decade, there has been a dramatic increase in our understanding of the pathogenesis o…
 
Lymphoma is a collection of cancers which develop in the lymphatic system andaffect the lymphocytes. The risk factors for lymphoma are not yet well-characterized and treatment depends on the type of lymphoma, it’s location andstage. Recent developments in the treatment of lymphoma include research intonovel chemotherapy regimens, chimeric antigen r…
 
Loading …

Korte handleiding

Google login Twitter login Classic login